Abstract
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.
Highlights
COVID-19 is currently well known among the general population
WO2016145142A1 relates to antiviral nucleotide and nucleoside therapeutic compositions
Molnupiravir is a promising oral treatment for COVID-19 that has been jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck
Summary
Imran 1, * , Mandeep Kumar Arora 2 , Syed Mohammed Basheeruddin Asdaq 3, * , Shah Alam Khan 4 , Saleh I. Alaqel 1 , Mohammed Kanan Alshammari 5 , Mohammed M. Alshehri 6 , Ahmed Subeh Alshrari 7 , Alreshidi Mateq Ali 8 , Ahmed Muteb Al-shammeri 9 , Bushra Dhuhayyan Alhazmi , Aishah Ali Harshan , Md. Tauquir Alam 1 and Abida 1. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh 11426, Saudi Arabia;. Medical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
